Melatonin Safety Profile
Melatonin is generally safe for short-term use in adults with only mild adverse effects, but it is NOT recommended as a first-line treatment for chronic insomnia, and specific populations including pregnant women, breastfeeding mothers, and young children should avoid it due to insufficient safety data. 1
Key Safety Findings
Common Adverse Effects
The most frequently reported side effects are:
- Daytime drowsiness (28.8% in real-world use, 1.66% in controlled trials) 2, 3
- Headache (25.1% in practice, 0.74% in trials) 2, 3
- Dizziness (0.74%) 2
- Sleep-related disturbances including vivid dreams and sleep fragmentation 4
- Mood changes and fatigue 5
These effects are typically mild, short-lived, and resolve spontaneously or upon discontinuation 2.
Dosing Considerations
The evidence base primarily supports 2-3 mg doses, though higher doses up to 15 mg have been studied 1, 4. A critical finding: melatonin functions primarily as a chronobiotic (timing signal) rather than a sedative-hypnotic, meaning timing of administration matters more than dose 6. The widespread practice of using supraphysiological doses at arbitrary bedtimes represents a fundamental misunderstanding of melatonin's mechanism 6.
For REM sleep behavior disorder, dosing starts at 3 mg and can increase by 3-mg increments to 15 mg 4.
High-Dose Safety (≥10 mg)
Studies examining doses ≥10 mg found:
- No significant increase in serious adverse events (Rate Ratio = 0.88) 7
- No increase in withdrawals due to adverse effects (0.93) 7
- Modest increase in minor adverse events like drowsiness, headache, dizziness (1.40 [1.15,1.69]) 7
However, 37% of high-dose studies failed to report adverse events at all, limiting confidence in these conclusions 7.
Populations Requiring Caution
Absolute Contraindications (Avoid Use)
- Pregnant women - No human safety data available 8
- Breastfeeding women - Insufficient evidence for safety 8
Relative Contraindications (Use with Extreme Caution)
- Pre-adolescent children - Long-term safety not established 8, 2
- Patients with epilepsy - Concerns raised but insufficient data 2
- Patients with asthma - Potential concerns noted 2
Special Populations Requiring Monitoring
Older Adults (>65 years):
- Increased risk due to polypharmacy and altered drug metabolism 9
- Avoid in patients taking antihypertensive medications - potential interactions affecting blood pressure and heart rate 5
- Consider starting at lower doses (0.25 mg) in neurodegenerative disease 4
- Clonazepam (alternative for RBD) is on the Beers Criteria list as potentially inappropriate in older adults, making melatonin a safer option in this context 4
Patients with Neurodegenerative Disease:
- Melatonin is "only mildly sedating" and preferred over benzodiazepines in Parkinson's disease and dementia with Lewy bodies 4
- Better tolerated than clonazepam which causes cognitive disturbances, falls, and delirium 4
Cardiovascular and Endocrine Concerns
Emerging evidence suggests potential effects on:
- Blood pressure and heart rate - particularly relevant with antihypertensive drug interactions 5
- Glucose metabolism - dosage and timing dependent 5
- Reproductive parameters - mechanism unclear 5
These effects appear influenced by dose timing and drug interactions, emphasizing the importance of circadian-appropriate administration 5.
Critical Clinical Pitfalls
Misdiagnosis Leading to Treatment Failure
Circadian rhythm disorders are frequently misclassified as primary insomnia 6. When melatonin is used to treat misdiagnosed insomnia (when the actual problem is delayed sleep phase disorder), it fails because:
- The timing is wrong (given at desired bedtime rather than 5-6 hours before natural sleep onset)
- The underlying phase misalignment is not addressed
- This leads to labeling the patient as a "melatonin non-responder" when the real issue was diagnostic error 6
Formulation Inconsistency
Over-the-counter preparations show substantial variability in actual melatonin content 6. This creates:
- Unpredictable dosing
- Difficulty reproducing clinical responses
- Safety concerns with unintended overdosing
Guideline Position on Chronic Insomnia
The American Academy of Sleep Medicine explicitly recommends AGAINST using melatonin for chronic insomnia (both sleep onset and maintenance) in adults 1. This recommendation is based on:
- Very low quality evidence
- Harms approximately equal to benefits
- Studies using 2 mg doses
This contrasts sharply with public perception of melatonin as a safe, effective sleep aid 6.
Long-Term Safety Gap
The most significant limitation is the lack of long-term safety data 8, 2, 9. Most studies monitored patients for ≤4 weeks, with the longest extending only to 29 weeks 2. Given increasing chronic use patterns, this represents a critical knowledge gap, particularly for:
- Children and adolescents using melatonin long-term
- Older adults on multiple medications
- Patients with chronic medical conditions
Practical Recommendations
When melatonin is appropriate (circadian disorders, RBD):
- Start with physiologic doses (0.5-3 mg)
- Time administration according to circadian principles, not arbitrary bedtime
- Use immediate-release formulations for most indications
- Monitor for drug interactions, especially antihypertensives
- Reassess need for continued use regularly
- Document specific adverse effects at follow-up
Avoid melatonin for: